Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

SILVER SPRING, Maryland — The cost of developing a drug-eluting stent (DES) has been pegged as somewhere north of $100 million, but that number has not deterred several device makers from wading into this end of the cardiovascular device pool.

DES post-approval no longer just an FDA after-thought